UnitedHealth Group (UNH) Stock Forecast & Price Target

UnitedHealth Group is supported by its unmatched scale across insurance and healthcare services, serving about 51 million members globally and using that breadth to drive pricing power, operating leverage, and strong cash flow. Its 3Q26 adjusted EPS of $4.69 beat consensus on an 88.4% medical loss ratio, while management lifted FY26 adjusted EPS guidance to at least $20.50 and signaled a clearer path into 2027. The outlook is further reinforced by Optum’s expanding role, with OptumHealth’s outperformance seen as durable, Optum Rx retaining clients in the high 90s, and the company targeting margin expansion across Medicare Advantage, Medicaid, and Optum over the next few years.

UnitedHealth Group is facing a negative fundamental setup as accelerating Medicare Advantage utilization, ongoing commercial cost pressures, and low visibility into near-term medical loss ratio trends point to earnings risk versus expectations. The company’s downside case assumes FY28 EPS about 10% below base case and a lower 15.0x multiple, reflecting pressure from IDR, specialty drugs, provider coding intensity, and v28 risk-model changes that may disproportionately affect UNH. Added uncertainty from network contracting, reimbursement risk in the government business, MA competition, and regulatory or DOJ scrutiny further weakens the outlook.